PF-Atlas › Clinical Trials › NCT02971839

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

VX-561 · Phase 2

Registry ID

NCT02971839

Phase

Phase 2

Status

Terminated

Drug / intervention

VX-561

Sponsor

Vertex Pharmaceuticals Incorporated

Start

2016-12

Enrollment

Locations

About this trial

This study will evaluate the efficacy and safety of CTP-656 in patients with cystic fibrosis (CF) who have a cystic fibrosis transmembrane conductance regulator (CFTR) gating mutation.

View NCT02971839 on ClinicalTrials.gov →

Explore related

All VX-561 trials All IPF trials

Related trials

VX-561 — NCT03911713

Medical disclaimer. This page summarizes public trial data for NCT02971839 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.